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INTRODUCTION 
The adrenal gland is a common site of disease, and detection of 
adrenal masses has increased with the expanding use of cross-sectional 
imaging. Radiology is playing a critical role in not only the detection of 
adrenal abnormalities but in characterizing them as benign or malignant. 
Abnormalities of the adrenal gland include primary neoplasm, 
metastases, hemorrhage, or enlargement of the adrenal gland from external 
hormonal stimulation. Adrenal masses can be divided into two physiologic 
categories based on whether they hypersecrete a hormone. 
Hyperfunctioning adrenal masses produce a hormone that results in a 
chemical imbalance and include pheochromocytomas, aldosteronomas, and 
cortisol or androgen-producing tumors. Nonfunctioning adrenal masses 
cause enlargement of the adrenal gland but no significant increased 
hormone production. Adrenal adenomas and metastases are the most 
common nonfunctioning adrenal masses. 
Adrenal masses are often discovered incidentally and are then 
termed adrenal incidentalomas. They are discovered many a time after an 
imaging procedure is performed that is unrelated to the adrenal gland. 
Usually, the patient has no signs of hormonal excess or obvious underlying 
malignancy. Less commonly, adrenal Masses are discovered as part of the 
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clinical workup for suspected adrenal disease for example, Cushing 
syndrome. 
The most common lesions, adrenal metastases and adenomas cannot 
be characterized so easily. This is usually because they are small, without 
specific diagnostic features, and frequently appear similar to each other 
when detected. The usual imaging dilemma is therefore to differentiate 
between these two very different lesions. The diagnosis has profound 
consequences for the patient.  
In a patient with an extraadrenal malignancy, the determination that 
an adrenal mass is metastatic often means the primary disease is incurable 
and palliative therapy is instituted. On the other hand, characterizing a 
lesion as benign in these circumstances potentially permits curative therapy 
for the primary disease.  
CHARACTERIZATION OF ADRENAL MASSES WITH 
CONTRAST ENHANCED CT 
CT: 
Most adrenal lesions are detected by CT, usually contrast-enhanced 
CT. Most benign and malignant lesions show variable enhancement on 
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dynamic contrast-enhanced CT. They can rarely be characterized by this 
test alone.  
There may be some imaging clues that permit early characterization 
such as significant interval growth, large size, and markedly irregular 
lesion. But the macroscopic features for the majority of lesions do not 
usually permit an easy diagnosis. Most benign and malignant lesions have 
very similar macroscopic appearances when detected. This is because they 
are generally small and homogeneous.  
A few may be confidently assigned as benign. These include cysts 
which show water density and myelolipomas, which usually contain 
macroscopic fat. So indeterminate lesions are those that are usually of 
moderate size (1–3 cm), homogeneous, and smooth walled.  
A dynamic contrast-enhanced CT cannot, on its own, characterize 
most of these lesions. 
But it has been known that unenhanced CT can be useful in 
differentiating benign from malignant disease. Most benign adenomatous 
lesions show a relatively low density on unenhanced CT because of the 
abundant presence of intracellular fat. Most malignant lesions are lipid-
poor and show higher attenuation values.  
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It is possible to choose an attenuation threshold that effectively 
differentiates most adenomas from malignant adrenal lesions [2]. An 
adrenal lesion measuring ≤ 10 HU is almost always benign. Unfortunately, 
only 70% of adenomas are lipid-rich, 30% being lipid poor, meaning that 
many lesions cannot be differentiated from metastases by this test. 
The ability to differentiate most lipid-rich benign lesions from 
indeterminate lipid-poor lesions has stood the test of time. Therefore the 
next suitable test is unenhanced CT.  
The placement of the region of interest (ROI) for density 
measurement is crucial for accurate adrenal characterization. The ROI 
should be at least one half to two thirds of the adrenal surface area. 
Otherwise noise effects from small ROIs will render the measurement 
inaccurate. 
Enhanced and Delayed Contrast-Enhanced CT 
Enhanced contrast-enhanced CT alone is not of much help to 
characterize an adrenal lesion. But delayed contrast-enhanced CT along 
with the enhanced study, enables characterization of most lipid-rich and 
lipid-poor adrenal lesions. 
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This is advantageous because almost all adrenal lesions can be 
differentiated by CT. And CT is faster, cheaper, and more available than 
MRI. Modern MDCT dose reduction programs render the test suitable for 
most patients with indeterminate adrenal incidentalomas  
Circulating contrast material within the adrenal gland that had 
previously been injected IV on dynamic contrast-enhanced CT tends to 
washout from adenomatous lesions far quicker than nonadenomatous 
lesions, particularly malignant lesions.  
If attenuation measurements of the adrenal gland were made on 
images performed 15 minutes after the contrast-enhanced CT, an 
attenuation threshold could be found in the delayed scan. The ability of the 
delayed scan alone to differentiate benign from malignant lesions found 
difficulty due to considerable overlap between adenomas and non 
adenomas. Further, delayed CT densitometry measurements depends on 
the type, total dose, and injection rate of intravenous contrast material, as 
well as the cardiac output of the patient, an absolute attenuation 
measurement on a delayed scan was not found to be very useful. 
Thus test sensitivity and specificity are suboptimal because the 
absolute attenuation values in enhanced and delayed scans of lipid-poor 
adrenal adenomas tended match that of lipid poor malignant lesions.  
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However, the fraction of contrast material that washed out of the 
adrenal gland from the enhanced to the delayed contrast-enhanced CT, 
helps characterize most adenomatous lesions. Thus, both lipid-rich and 
lipid-poor adenomatous lesions can be characterized  with this single test.  
If lesions show an absolute contrast-enhanced percentage washout— 
the fraction of the difference between the enhanced and delayed contrast-
enhanced CT divided by the absolute enhancement (the increase in adrenal 
attenuation from unenhanced CT to enhanced contrast-enhanced CT)—of 
greater than 60%, then lesions are assumed to be benign.  
A relative contrast- enhanced percentage washout is also calculated, 
and a value of 40% or greater is used. This is calculated by assigning the 
unenhanced CT lesion attenuation value as zero and calculating the 
fraction using the same numerator as absolute contrast-enhanced 
percentage washout, but the denominator of the contrast-enhanced CT 
attenuation value alone.  
Lesions showing an absolute contrast-enhanced percentage washout 
and relative contrast-enhanced percentage washout of less than 60% and 
40%, respectively, are consistent with non adenomatous lesions, usually 
metastases. 
The absolute contrast-enhanced percentage washout and relative 
contrast-enhanced percentage washout test accuracy using 10-minute 
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delayed contrast-enhanced CT has also been calculated and found to be 
highly accurate.  
But use of the 15-minute delayed image it is recommended as 
standard for this adrenal CT protocol to calculate the fractional washout. 
It has been proposed that Relative Percent Washout and Absolute 
Percent Washout tests are so effective  for differentiating adenomas from 
nonadenomas that other imaging tests (including MR and PET) should 
only be needed in unusual circumstances 
IMAGING ALGORITHM 
 
Figure 5
Aim of the Study 
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AIM OF THE STUDY  
To assess the accuracy of Contrast Enhanced CT - Washout study in 
characterizing adrenal masses as benign or malignant, i.e as adenomas or 
non adenomas. 
Relevant Anatomy 
and  Physiology 
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ANATOMY AND PHYSIOLOGY OF ADRENAL GLANDS 
Anatomically, the adrenal glands are located in the retroperitoneum 
superior to the kidneys, bilaterally. They are surrounded by an adipose 
capsule and renal fascia. They are found at the level of the 12th thoracic 
vertebra. Each adrenal gland has two distinct structures, the outer adrenal 
cortex and the inner medulla, both of which produce hormones. The cortex 
mainly produces cortisol, aldosterone and androgens, while the medulla 
chiefly produces epinephrine and norepinephrine. The combined weight of 
the adrenal glands in an adult human ranges from 7 to 10 grams.  
Adrenal Gland Anatomy 
 
Figure 1 
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CORTEX 
The adrenal cortex is devoted to the synthesis of corticosteroid and 
androgen hormones. In contrast to the direct innervation of the medulla, 
the cortex is regulated by neuroendocrine hormones secreted from the 
pituitary gland which are under the control of the hypothalamus, as well as 
by the renin-angiotensin system. 
The adrenal cortex comprises three zones, or layers.  
Zona glomerulosa 
The outermost layer, the zona glomerulosa is the main site for 
production of mineralocorticoids, mainly aldosterone, which is largely 
responsible for the long-term regulation of blood pressure.  
Zona fasciculata 
Situated between the glomerulosa and reticularis, the zona 
fasciculata is responsible for producing glucocorticoids, such as 11-
deoxycorticosterone, corticosterone, and cortisol in humans. Cortisol is the 
main glucocorticoid. 
Zona reticularis 
The inner most cortical layer, the zona reticularis produces 
androgens, mainly dehydroepiandrosterone (DHEA) DHEA sulfate 
(DHEA-S), and androstenedione (the precursor to testosterone) in humans.  
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MEDULLA 
The adrenal medulla is the core of the adrenal gland, and is 
surrounded by the adrenal cortex. It secretes approximately 20% 
norepinephrine and 80% epinephrine. These are the major hormones 
underlying the fight-or-flight response. 
Adrenal Gland Schematic section and Histology 
 
Figure 2 
Blood supply 
There are usually three arteries that supply each adrenal gland: 
The superior suprarenal artery is provided by the inferior phrenic 
artery. The middle suprarenal artery is provided by the abdominal aorta. 
The inferior suprarenal artery is provided by the renal artery. 
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Venous drainage of the adrenal glands is achieved via the suprarenal 
veins: 
The right suprarenal vein drains into the inferior vena cava. The left 
suprarenal vein drains into the left renal vein or the left inferior phrenic 
vein. 
The adrenal glands and the thyroid gland are the organs that have the 
greatest blood supply per gram of tissue. Up to 60 arterioles may enter 
each adrenal gland. This may be one of the reasons lung cancer commonly 
metastasizes to the adrenals. 
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NORMAL CT ANATOMY 
At CT, the adrenal glands appear as triangular or crescentic soft 
tissue structures draped over the upper poles of the kidneys immediately 
anterolateral to the crura of the diaphragm. The two limbs of each adrenal 
gland appear as thin strands that join superiorly. 
 
Normal CT axial sectional Anatomy 
 
Figure 3 
 
The right adrenal gland is located in an area just superior to the right 
kidney, medial to the right lobe of the liver, lateral to the crus of the right 
hemidiaphragm, and posterior to the inferior vena cava. Its shape is 
variable but may resemble an elongated comma lying in the crease 
between the liver and the crus of the diaphragm. It also may be shaped like 
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an inverted letter V or Y. The lateral limb of the adrenal gland lies close to 
the right lobe of the liver and can sometimes be difficult to separate from 
the surface of the liver. 
The left adrenal gland is located superior to and extends anterior to 
the upper pole of the left kidney in a triangle formed by the left lateral 
margin of the aorta, the posterior surface of the body and tail of the 
pancreas, and the anterior superior medial surface of the upper pole of the 
left kidney. It can be shaped like an inverted letter V or Y, an inverted or 
reversed letter L, or it may be triangular. 
Coronal CT Anatomy 
 
Figure 4 
Coronal reformatted image from helical CT data shows the 
triangular shape of the adrenal gland (arrows) and its relationship to the 
kidneys and diaphragm 
Review 
of 
Literature 
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REVIEW OF LITERATURE 
Melvyn Korobkin and Frederick . J Brodeur et al studied contrast 
enhancement washout curves of 52 adenomas and 24 non adenomas. The 
optimal threshold value and the corresponding sensitivity and specificity 
were calculated for the diagnosis of adenoma. Also the absolute and 
relative percentage washouts were calculated at time delays from 5 to 45 
minutes after contrast enhancement. 
The mean percentage enhancement washout for adenomas was 51% 
at 5 minutes and 70% at 15 minutes, compared with 8% and 20% 
respectively for non adenomas. The sensitivity and specificity of 
diagnosing adenomas was higher at the 15 minute scan than at the 5 minute 
delayed scan.  Based on the 15 minute delayed scan’s calculation of 
percentage enhancement washout with 60 HU as threshold, there was a 
sensitivity of 88% and specificity of 96%. For the relative percentage 
washout with a 37HU threshold, the sensitivity and specificity both were 
96%. 
Elaine M. Caoili, MD et al evaluated One hundred sixty-six adrenal 
masses were evaluated with a protocol consisting of unenhanced CT, and, 
for those with attenuation values greater than 10 HU, contrast material–
enhanced and delayed enhanced CT. Attenuation values and enhancement 
 16 
  
washout calculations were obtained. An adenoma was diagnosed if a mass 
had an attenuation value of 10 HU or less at unenhanced CT or a 
percentage enhancement washout value of 60% or higher. 
The final diagnosis was adenoma in 127 masses and nonadenoma in 
39. Masses measuring more than 10 HU on unenhanced CT scans were 
confirmed at biopsy (n _ 28) or were examined for stability or change in 
size at follow-up CT performed at a minimum interval of 6 months (n _ 
33). Thirty-six (92%) of 39 nonadenomas and 124 (98%) of 127 adenomas 
were correctly characterized.  The sensitivity and specificity of this 
protocol were 98% and 92%, respectively. This protocol correctly 
characterized 160 (96%) of 166 masses. The study concluded that With a 
combination of unenhanced and delayed enhanced CT, nearly all adrenal 
masses can be correctly categorized as adenomas or nonadenomas. 
Giles W. L.Boland et al analyzed ten CT reports, from which 
individual adrenal lesion density measurements were obtained for 495 
adrenal lesions (272 benign lesions and 223 malignant lesions). Threshold 
analysis generated a range of sensitivities and specificities for lesion 
characterization at different density thresholds. The study found that 
sensitivity for characterizing a lesion as benign ranged from 47% at a 
threshold of 2 H to 88% at a threshold of 20 H. Similarly, specificity 
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varied from 100% at a threshld of 2 H to 84% at a threshold of 20 H. It was 
concluded that the attempt to be absolutely certain that an adrenal lesion is 
benign may lead to an unacceptably low sensitivity for lesion 
characterization. The threshold chosen will depend on the patient 
population and the cost benefit approach to patient care. 
Song et al. study showed that in 973 consecutive patients with 1,049 
incidental adrenal masses adenomas accounted for 75% of incidental 
masses, of which 78% were lipid rich adenomas with native CT 
attenuation values of less than 10 HU. 
Lee et al. first reported that unenhanced CT densitometry could 
effectively differentiate many adrenal adenomas from nonadenomatous 
disease. They found that the mean attenuation of adenomas (−2.2 HU) was 
significantly lower than that of nonadenomas (28.9 HU). By using a 
threshold of 0 HU, these lesions could be then differentiated with 
sensitivity and specificity of 47% and 100%, respectively. 
Blake et al. study showed that an unenhanced CT attenuation value 
of 0 HU or lower should supersede the contrast washout characteristics and 
that noncalcified, nonhemorrhagic adrenal lesions with a native density of 
43 HU or more should be considered indeterminate and suspicious for 
malignancy irrespective of their contrast washout characteristics. 
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Elaine M. Caoili1 and Melvyn Korobkin et al studied eighteen 
proven lipid-poor adenomas, 56 lipid-rich adenomas, and 40 adrenal 
nonadenomas. They underwent CT before, immediately  after, and 15 min 
delay after IV contrast injection.  
The mean unenhanced value of the lipid-poor adenomas was 
significantly higher than that of the lipid-rich adenomas (p < 0.001) but 
was not significantly different from the value of the nonadenomas (p = 
0.24). The mean enhanced attenuation value of the lipid-poor adenomas 
was significantly higher than that of the lipid-rich adenomas (p < 0.01) but 
was not significantly different from that of the nonadenomas (p = 0.03). 
The mean delayed contrast-enhanced attenuation value of the lipid-poor 
adenomas was significantly higher than that of the lipid-rich adenomas (p 
< 0.001) but was not significantly different than that of the nonadenomas 
(p = 0.03). 
The mean enhancement, enhancement washout, and percentage 
enhancement washout were all significantly lower (p < 0.001) for the 
nonadenomas than for the adenomas.  
The relative percentage enhancement washout of the lipid poor 
adenomas was significantly lower than that of the lipid-rich adenomas (p < 
0.001). Nevertheless, the relative percentage enhancement washout was 
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still significantly higher for lipid-poor adenomas than that of the 
nonadenomas (p < 0.001). The optimal threshold value of percentage 
enhancement washout for both lipid-poor and lipid-rich adenomas was 
60%. For the relative percentage enhancement washout for lipid-poor 
adenomas, the optimal threshold was 40%. 
Giovanni Foti retrospectively evaluated the accuracy of unenhanced 
attenuation and relative percentage wash-in ratio in early, - arterial and 
portal venous phase, biphasic CT in differentiating adrenal adenomas from 
metastatic lesions. 
One hundred seven adrenal masses in 86 patients were evaluated. 
Diagnosis was achieved with percutaneous biopsy (n = 6), surgery (n = 
13), and at least 1 year of imaging follow-up (n = 88). Unenhanced, arterial 
phase, and portal phase scans were obtained. Diameter and absolute 
attenuation values in each phase of CT were measured. Relative percentage 
wash-in ratio was calculated. 
The final diagnosis was metastasis in 51 cases and adenoma in 56 
cases. A significant difference was found between benign and malignant 
lesions in regard to diameter (p = 0.001), unenhanced CT attenuation (p = 
0.001), and relative percentage wash-in ratio from the arterial to the portal 
venous scan (p = 0.014). In the differentiation of benign from malignant 
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lesions, the sensitivity, specificity, positive predictive value, negative 
predictive value, and accuracy of unenhanced CT attenuation (at an 11-HU 
threshold) were 98%, 86%, 86%, 98%, and 92%, and those of relative 
percentage wash-in ratio from the arterial to the portal venous phase were 
94%, 77%, 79%, 93%, and 85%. 
Boland et al reported that lipid-poor adrenal lesions, which contain a 
low lipid-to-water proton ratio, cannot generally be characterized by 
chemical shift methods, as their signal intensity is unchanged on opposed-
phase images. These lesions are then considered indeterminate on the basis 
of chemical shift MR images. 
B K Park et al retrospectively assessed adrenal incidentalomas 
detected by triphasic helical CT using modified relative percentage of the 
enhancement washout (mRPEW) values. 42 adrenal incidentalomas in 35 
patients were detected on CT and confirmed by either pathological 
examination or follow-up CT examination. The mRPEW values were 
calculated using the attenuation values of the adrenal masses seen on the 
images from portal phase and delayed phase CT performed 3 min after 
intravenous injection of contrast material. The diagnostic accuracy of an 
adenoma was obtained using the mRPEW values. The final diagnosis was 
an ‘‘adenoma’’ and a ‘‘metastasis’’ in 9 and 33 cases, respectively. The 
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mRPEW values of the adenomas and metastases ranged from 5.8% to 
59.4% and from –18.8% to 25%, respectively (p,0.05). An mRPEW value 
of 20% yielded the best accuracy of 88% (37/42) for an adenoma. mRPEW 
values .25% and #5% had a positive predictive value of 100% (3/3) and a 
negative predictive value of 100% (15/15), respectively. They concluded 
that a substantial number of adrenal incidentalomas may be characterized 
using the mRPEW values from triphasic helical CT. 
Sung-Woo Park et al attempted to resolve the dilemma regarding 
indeterminate adrenal lesions by assessing the relative percentage washout 
of adrenal lesions after contrast-enhanced CT. In a multicenter study, they 
determined the accurate cut-off value and delayed time of the washout rate 
for adrenal adenomas by final pathologic diagnosis. 244 patients 
undergoing adrenalectomies at 5 university hospitals in Pusan, Korea 
between 2005 and 2009 were reviewed. They calculated the mean value of 
Housfield units in residual lesions _ 3 times using the region of interest 
(ROI) during pre-operative non-enhancing CT scans, and early and 
delayed images in enhanced CT scans. We used ROC curves to determine 
the specificity and sensitivity of non-enhanced CT scans and the washout 
rate according to the diagnostic criteria for adrenal adenomas. They 
divided the patients into the following 2 groups:- adrenal adenoma group 
(n_138); and non-adrenal adenoma group (n_106). There was no 
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significant difference in age, gender, and right and left findings between 
the two groups. Based on the ROC curves, the specificity and sensitivity 
was 45.7% and 97% for the non-enhancing CT scans (HU_10), and 93.9% 
and 95.8% for the 15-minute washout rate (_55%) respectively. 
Constantino S. Peña et al determined  whether computed 
tomographic (CT) scans and attenuation measurements on contrast 
material–enhanced and nonenhanced CT scans could be used to 
characterize adrenal masses, in particular, to characterize these lesions by 
using adrenal washout characteristics at contrast-enhanced CT. Eighty-six 
patients (49 men, 37 women; age range, 29–86 years; mean age, 72 years) 
with 101 adrenal lesions depicted at contrast-enhanced CT underwent 
delayed (mean, 9 minutes) enhanced scanning. Seventy-eight patients also 
underwent nonenhanced CT. Mean diameter of the benign lesions was 2.1 
cm (range, 1.0–4.2 cm); mean diameter of the malignant lesions was 2.3 
cm (range, 1.0–4.1 cm). Region-of-interest measurements were obtained at 
nonenhanced, dynamic enhanced, and delayed enhanced CT and were used 
to calculate a relative percentage washout as follows: 1 − (Hounsfield unit 
measurement on delayed image ÷ Hounsfield unit measurement on 
dynamic image) × 100%. Ninety-nine of 101 lesions were correctly 
characterized as benign or malignant with a relative percentage washout 
threshold of 50% on delayed scans; benign lesions demonstrated more than 
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50% washout; and malignant lesions, less than 50% washout. Two benign 
lesions demonstrating less than 50% washout were characterized as benign 
by using conventional CT. They concluded that  calculation of relative 
percentage washout on dynamic and delayed enhanced CT scans may lead 
to a highly specific test for adrenal lesion characterization, reduce the need 
for, and possibly obviate, follow-up imaging or biopsy. 
D H Szolar et al measured the changes in wash-in and washout of 
contrast material on contrast material-enhanced computed tomographic 
(CT) scans in patients with adrenal adenomas and nonadenomas. One 
hundred twenty-two patients with 135 adrenal masses (74 adenomas, 61 
nonadenomas) underwent helical CT. Unenhanced CT was followed by 
enhanced CT at 30, 60, and 90 seconds and 3, 10, and 30 minutes. The 
adenomas enhanced significantly more than the nonadenomas at 60 
seconds (P < .001), but the percentage enhancement of the adenomas was 
significantly greater than that of the nonadenomas at 30, 60, and 90 
seconds (P < .001). At 3, 10, and 30 minutes, the absolute percentage loss 
of enhancement and the relative percentage loss of enhancement were 
significantly greater for the adenomas than for the nonadenomas (P < 
.001). Delayed enhanced CT at 10 minutes (sensitivity, 92%; specificity, 
95%) and 30 minutes (sensitivity, 97%; specificity, 100%) was more 
accurate for differentiation of adenomas and nonadenomas than 
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unenhanced CT (sensitivity, 82%; specificity, 95%). They concluded that 
adrenal adenomas exhibit greater washout of contrast material than do 
adrenal nonadenomas. The percentage change in washout of contrast 
material is a useful adjunct to absolute CT attenuation values in 
differentiation of adrenal adenomas and nonadenomas.  
Takuro Kamiyama et al retrospectively examined the diagnostic 
values of individual parameters obtained from unenhanced and 35-second 
and 5-minute contrast material–enhanced (enhanced) computed 
tomography (CT) in distinguishing adenomas, particularly lipid-poor 
adenomas, from nonadenomas and to determine the best diagnostic method 
by using these parameters. 
The study population consisted of 61 patients (20 men and 41 
women; mean age, 58 years) with 68 adrenal masses (53 adenomas and 15 
nonadenomas). In each patient, unenhanced CT was followed by 35-
second and 5-minute enhanced CT. Adenomas were classified as 30 lipid-
rich (_10 HU) and 23 lipid-poor (_10 HU) adenomas by using unenhanced 
attenuation. The diagnostic parameters were tumor size, unenhanced 
attenuation, 35-second and 5-minute enhanced attenuation, wash-in and 
washout attenuation, percentage enhancement washout ratio (PEW), and 
relative PEW (RPEW). The sensitivity, specificity, and accuracy for 
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diagnosing adenomas were calculated by using a threshold level of each 
parameter determined by the least sum of false-positive and false-negative 
cases and a combination of the threshold levels with 100% specificity. The 
best results were obtained by using a combination of the threshold levels 
with 100% (15 of 15) specificity (presence of at least one of the following 
criteria for diagnosing adenomas: unenhanced attenuation of _19 HU, 5-
minute attenuation of _50 HU, PEW of _45%, and RPEW of _31%). 
Sensitivity was 94% (50 of 53) or 87% (20 of 23) and accuracy was 96% 
(65 of 68) or 92% (35 of 38) for diagnosing total adrenal adenomas or 
lipid-poor adenomas, respectively. 
They concluded that combining the diagnostic parameters of the CT 
protocol can yield diagnostic results comparable to those with previously 
reported longer dynamic enhanced CT protocols. 
John K. Yoon et al reported a case of a 50 year old man for whom 
Adrenal CT  was then performed, with unenhanced, 60-second enhanced, 
and 15- minute delayed imaging. The right adrenal nodule measured 2.0 × 
1.9 cm in maximum axial dimensions. Region of interest measured 37 H 
on the unenhanced images, 127 H on the 60-second contrast enhanced 
images, and 62 H on the 15-minute delayed images, representing 72% 
absolute contrast enhancement washout. The patient underwent a 
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laparoscopic right adrenalectomy 6 weeks later, and the diagnosis of right 
adrenal pheochromocytoma was pathologically confirmed. This case of an 
incidental pheochromocytoma showing contrast medium washout greater 
than 50% on delayed imaging reiterated the importance of performing a 
biochemical profile in any patient with an incidentally discovered adrenal 
mass, regardless of clinical signs and symptoms. 
 
 
Materials 
& 
Methods 
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MATERIALS AND METHODS 
STUDY POPULATION  
The study group includes a total 50 Patients with 54 adrenal masses 
who have come to the Department of Radiology at Madras Medical 
College. 
STUDY PLACE:  
Barnard Institute of Radiology, Madras Medical College and 
Government General Hospital, Chennai 
STUDY DESIGN: 
Prospective Study 
INCLUSION  CRITERIA   
Patients with adrenal masses, measuring more than 1cm, with 
Hounsfield Unit more than 10. 
EXCLUSION  CRITERIA   
Pregnant women 
Severe hypersensitivity or previous allergic reactions  
Critically ill patients 
Patients in renal failure 
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The study was approved by our institutional ethical committee, and 
informed consent was obtained from all the patients. The examinations 
were performed during the period from June 2009 to October 2011.  
CT MACHINES USED IN THE STUDY 
Philips Brilliance 64 Slice 
 
Figure 6 
Toshiba Asteion 4 Slice 
 
Figure 7 
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DATA ACQUISITION 
Adrenal masses were evaluated with an adrenal CT imaging 
protocol. The dedicated adrenal CT protocol consisted of initial 
densitometry of the mass on unenhanced CT scans. If the mass had an 
attenuation of 10 HU or less, it was assumed to be benign and the masses 
were excluded from the study. Thus, twenty masses with HU below 10 
were excluded. 
Two masses with grossly visible fatty components (less than or 
equal to _30 HU) were presumed to be myelolipomas and were excluded 
from the study. Ten additional masses were excluded because of 
inadequate follow-up.  
A diagnosis was established in the final study group of 54 masses 
when histologic proof was obtained at surgery or percutaneous biopsy.  
All patients with adrenal masses that had attenuation values greater 
than 10 HU at unenhanced imaging underwent enhanced CT imaging 60 
seconds after intravenous administration of contrast material and then 
underwent delayed enhanced CT imaging at 15 minutes.  
The scans were done with a Philips Brilliance 64 slice CT scanner or 
Toshiba Asteion 4 slice CT scanner. Enhancement washout percentages 
were calculated for these masses. 
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To diagnose an adrenal mass as an adenoma, we used the previously 
reported thresholds of 60% or higher for absolute percentage washout and 
40% or higher for relative enhancement washout.  
 Parameters for the unenhanced and delayed enhanced examinations 
with the CT scanners were KVp (Peak KV) of 120 kVp, Slice Thickness of 
2mm and Slice Interval of 5mm. Enhanced scans were obtained after 
intravenous injection of 40 mL of iohexol 350 (Omnipaque). 
IMAGE ANALYSIS 
CT attenuation values were measured by using a circular region of 
interest on images of the adrenal lesion in question. The region of interest 
covered at least one-half of the mass, excluding cystic, calcified, or 
necrotic regions. The edges of the adrenal lesion were avoided to prevent 
partial volume averaging.  
The enhancement washout percentages were calculated with the 
following equation 
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CONTRAST WASHOUT FORMULAE 
 
Figure 8 
The maximal diameters and the right or left side locations of the 
adrenal masses were also recorded.  
Statistical analysis of variance was undertaken to examine the 
significance of the differences between the adenomas and nonadenomas in 
terms of mean mass size, mean attenuation value at unenhanced CT, mean 
attenuation value at enhanced CT, mean attenuation value at delayed 
enhanced CT, mean percentage of enhancement washout, and mean 
relative percentage of enhancement washout. 
A p value less than .05 was considered to indicate a statistically 
significant difference. The threshold values of 60% or higher for absolute 
percentage enhancement washout and 40% or higher for relative 
percentage enhancement washout used in the diagnosis of adenoma were 
established in prior investigations 
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Protocol
Plain HU > 10
Lipid rich adenoma CT Washout study
Excluded Absolute Percent Washout 
> 60%
Adenoma Non adenoma
No Yes
Yes No
Relative Percent Washout 
> 40%
Yes No
 
Figure 9
Results 
& 
Statistical Analysis 
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RESULTS   
Number: 
The final clinical diagnosis was adrenal adenoma for 25 masses and 
nonadenoma for 29 masses, confirmed at pathologic examination. 
 
 
 
 
 
 
 
 
 
 
Figure 10 
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Adenomas were more often found in the right (n = 14) than in the 
left (n = 11) adrenal gland.  
  Nonadenomas were found in the left adrenal gland in 13 cases and in 
the right adrenal gland in 16 cases.  
 
 
 
 
 
 
 
 
Figure 11
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Sex: 
The patient population with adrenal adenomas consisted of 11 
women and 14 men with a mean age of 48 years (range, 23–73 years).  
In 1 of these patients, there were bilateral adrenal masses.  
The patient population with nonadenomas consisted of 12 women 
and 17 men with a mean age of 55 years (range, 26–75 years).  2 patients 
had bilateral adrenal masses. 
 
 
Figure 12 
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The average maximal diameter of the adenomas was 3.5 cm (range, 
2.5–5.1 cm, with Standard deviation of 0.6). 
Nonadenomas were larger (mean size, 4.2 cm; range, 2.7–6.3 cm, 
with Standard deviation of 1.0). It was found to be statistically significant 
with a p value of 0.005.  
 
 
 
 
 
 
 
 
 
 
Figure 13 
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The mean attenuation values of adenomas and nonadenomas on 
unenhanced, enhanced, and delayed enhanced CT scans are shown in 
Table 1.  
Table 1: Mean attenuation values of Adrenal Masses 
 Unenhanced Enhanced Delayed 
Adenoma 23.5 75.3 41.6 
Non adenoma 27.2 66.2 45.9 
 
The nonadenomas included 26 metastases, two pheochromocytomas, 
one adrenal cortical carcinoma.  
The primary malignancies in the 26 patients who had adrenal 
metastases were the following: lung cancer (n =17), esophageal cancer (n = 
2), renal cancer (n = 2), tongue cancer (n = 1), rectal cancer (n = 1) and 
breast cancer (n =3). 
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STATISTICAL ANALYSIS 
Mean unenhanced attenuation value: 
The mean unenhanced value of the adenomas (23.5 HU, with 
Standard deviation of 4.9) was significantly different from that of the non-
adenomas (27.2 HU with Standard deviation of 1.0). The  p value was 
0.022).  
Mean enhanced attenuation value: 
The mean attenuation value of the adenomas at enhanced CT (75.3 
HU  with Standard deviation of  13.1) was significantly higher than that of 
the nonadenomas ( 66.2 HU with Standard deviation of 10.6). The p value 
was 0.007 
Mean delayed attenuation value: 
The mean attenuation value of the adenomas at delayed enhanced 
CT (41.5 HU with Standard deviation of 7.3) was lower than that of the 
nonadenomas (45.9 HU with Standard deviation of 8.8). The p value was 
0.059, not found to be statistically significant. 
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Figure 14 
 
 
Scatterplots of HU values 
 
 
 
 
Figure 15 
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T-Test 
Table 2 : Group Statistics 
 
 Path Result N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
Size Adenoma 25 3.464 .6297 .1259 
Non-adenoma 29 4.159 1.0387 .1929 
Plain Adenoma 25 23.520 4.9086 .9817 
Non-adenoma 29 27.248 6.4066 1.1897 
Enhanced Adenoma 25 75.256 13.0951 2.6190 
Non-adenoma 29 66.210 10.6104 1.9703 
Delayed Adenoma 25 41.580 7.3367 1.4673 
Non-adenoma 29 45.879 8.8179 1.6374 
Absolute 
washout 
Adenoma 25 65.544 5.3920 1.0784 
Non-adenoma 29 54.441 11.8583 2.2020 
Relative 
washout 
Adenoma 25 44.616 3.6383 .7277 
Non-adenoma 29 30.645 7.0130 1.3023 
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Table 3 : Independent Samples Test 
 
  t-test for Equality of Means 
  
t 
 
df 
 
Sig. 
(2-
tailed)
 
Mean 
Difference
 
Std. 
Error 
Difference 
 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Size -
2.912 52 .005 -.695 .2385 -1.1733 -.2159 
  -
3.015 46.999 .004 -.695 .2304 -1.1581 -.2312 
Plain -
2.370 52 .022 -3.728 1.5730 -6.8848 -.5718 
  -
2.417 51.342 .019 -3.728 1.5424 -6.8243 -.6322 
Enhanced 2.804 52 .007 9.046 3.2265 2.5713 15.5200
  2.760 46.176 .008 9.046 3.2774 2.4493 15.6420
Delayed -
1.929 52 .059 -4.299 2.2291 -8.7723 .1737 
  -
1.955 51.945 .056 -4.299 2.1987 -8.7114 .1128 
Absolute 
washout 4.309 52 .000 11.103 2.5766 5.9322 16.2730
  4.528 40.335 .000 11.103 2.4519 6.1484 16.0568
Relative 
washout 8.967 52 .000 13.971 1.5581 10.8447 17.0976
  9.365 43.290 .000 13.971 1.4918 10.9633 16.9791
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Distribution of values 
Although the means of the attenuation values at enhanced CT and 
the attenuation values at delayed enhanced CT for lipid-poor adenomas 
and nonadenomas were significantly different, there was too much overlap 
among the individual values of the two groups to permit differentiation 
between them for any individual mass. 
 
Table 4:  Mean Washout Percentages 
 Absolute percent washout Relative percent washout
Adenoma 65.5 % 44.6 % 
Non adenoma 54.4 % 30.6 % 
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Figure 16 
 
Scatterplots  of Washout  Values 
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Absolute percentage enhancement washout: 
The absolute percentage enhancement washout value of the 
adenomas (65.5% with Standard deviation of 5.4) was significantly higher 
than that of the nonadenomas (54.4% with Standard deviation of 11.9). 
The p  value was <0.001**.  (** - significance at 1% level) 
Table 5: Result Absolute percentage washout * Pathological Result 
Crosstab 
    Path Result Total 
    
Adeno
ma 
Non-
adenoma  
Result 
Abs 
Adenoma Count 24 2 26 
    % within 
Result Abs 92.3% 7.7% 100.0% 
    % within Path 
Result 96.0% 6.9% 48.1% 
  Non-
adenoma 
Count 1 27 28 
    % within 
Result Abs 3.6% 96.4% 100.0% 
    % within Path 
Result 4.0% 93.1% 51.9% 
Total Count 25 29 54 
  % within 
Result Abs 46.3% 53.7% 100.0% 
  % within Path 
Result 100.0% 100.0% 100.0% 
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Table 6 : Chi-Square Tests 
 
  
Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square 
42.696 
(b) 
1 .000   
Continuity 
Correction(a) 39.202 1 .000   
Likelihood 
Ratio 51.833 1 .000   
Fisher's Exact 
Test    .000 .000 
Linear-by-
Linear 
Association 
41.906 1 .000   
N of Valid 
Cases 54     
 
a   Computed only for a 2x2 table 
b   0 cells (.0%) have expected count less than 5. The minimum 
expected count is 12.04. 
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Relative percentage enhancement washout value: 
The relative percentage enhancement washout value of the 
adenomas (Mean 44.6%, with Standard deviation of 3.6) was also 
significantly higher than that of the nonadenomas (30.6%, with Standard 
deviation of 7.0) The p value was <0.001**. (** - significance at 1% level) 
Table 7: Result Relative percent washout * Pathological Result Crosstab 
    Path Result Total 
    Adenoma
Non-
adenoma   
Result 
Rel 
Adenoma Count 23 3 26 
  % within 
Result Rel 88.5% 11.5% 100.0%
  % within 
Path 
Result 
92.0% 10.3% 48.1% 
 Non-
adenoma 
Count 2 26 28 
  % within 
Result Rel 7.1% 92.9% 100.0%
  % within 
Path 
Result 
8.0% 89.7% 51.9% 
Total Count 25 29 54 
 % within 
Result Rel 46.3% 53.7% 100.0%
 % within 
Path 
Result 
100.0% 100.0% 100.0%
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Table 8 : Chi-Square Tests 
 
  Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 35.856(b) 1 .000   
Continuity 
Correction(a) 32.660 1 .000   
Likelihood Ratio 41.557 1 .000   
Fisher's Exact 
Test    .000 .000 
Linear-by-Linear 
Association 35.192 1 .000   
N of Valid Cases 54     
 
a   Computed only for a 2x2 table 
b   0 cells (.0%) have expected count less than 5. The minimum 
expected count is 12.04. 
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Figure 18 
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Absolute percent washout 
The use of a threshold of 60% in the differentiation of adenomas 
from nonadenomas resulted in a sensitivity of 96% (24 of 25 masses) and a 
specificity of 93% (27 of 29 masses) 
Table 9 : APW Outcome vs Pathological Result 
 Adenoma Non adenoma 
Test + ve 24 2 
Test –ve 1 27 
 
 APW > 60%  Ö Test + ve  Ö  Adenoma 
 APW < 60%  Ö Test  - ve  Ö  Non adenoma 
 
Table 10 : Statistical Evaluation of Absolute Percent Washout 
Sensitivity 96.00% 
Specificity 93.10% 
PPV 92.31% 
NPV 96.43% 
 
There was 1 adenoma that did not meet the 60% threshold. The 
percentage enhancement washout measurements for this mass was 57.4% 
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Two nonadenomas had absolute percentage enhancement washout 
measurements above the 60% threshold. These washout measurements 
were 99.2% and 65.1%. Both were metastases.  
Relative percent washout 
The use of a relative percentage enhancement washout threshold 
value of 40% in the differentiation of the adenomas resulted in a sensitivity 
of 92% (23 of 25 masses) and a specificity of 89.66% (26 of 29 masses).  
Table 11 : RPW Outcome vs Pathological Result 
 Adenoma Non adenoma 
Test + ve 23 3 
Test –ve 2 26 
 RPW > 40%  Ö Test + ve  Ö  Adenoma 
 RPW < 40%  Ö Test  - ve  Ö  Non adenoma 
 
Table 12 : Statistical Evaluation of Relative Percent Washout 
Sensitivity 92.00% 
Specificity 89.66% 
PPV 88.46% 
NPV 92.86% 
 
The relative percentage enhancement washout measurements for the 
2 adenomas that did not meet the 40% relative percentage enhancement 
 51 
  
80
90
100
APW RPW
96
9293.1
89.66
Pe
rc
en
ta
ge
APW & RPW
Sensitivity
Specificity
threshold were 37.7%, 34.9%.1adenoma did not meet either threshold 
criteria. 
3 Non adenomas were wrongly characterised with relative percent 
washout. The relative percentage enhancement washout measurements for 
these masses were 41.5%, 42.4% and 47% respectively. 
 
Table 13 APW & RPW 
 Sensitivity Specificity 
APW 96.00 % 93.1 % 
RPW 92.00 % 89.66 % 
 
 
 
 
 
 
 
 
 
 
Figure 19 
Discussion 
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DISCUSSION 
In patients with a known extraadrenal primary neoplasm, 
differentiation of an adenoma from a metastasis is the principal reason an 
adrenal mass is characterized.  
  Nonadenomas such as pheochromocytomas and primary adrenal 
malignancies are rare, and the former can usually be diagnosed by virtue of 
their clinical and biochemical features.  
There are two independent properties of adrenal adenomas that can 
be exploited in characterizing them at CT.  
First, most adenomas contain large amounts of intracellular lipid, 
resulting in lower attenuation values at unenhanced CT than nonadenomas. 
Second, all adenomas, including those without substantial lipid 
content, tend to have a more rapid loss of attenuation value soon after 
enhancement with intravenous contrast material.  
The purpose of this study was to assess the accuracy, sensitivity and 
specificity of this method.  
Absolute percentage enhancement washout threshold of 60% 
correctly diagnosed 24 of 25 adenomas. This was with a sensitivity of 
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96%, specificity of 93.1%. The positive and negative predictive values 
were 92.3% and 96.4% respectively. 
Absolute percentage washout failed to correctly characterise two 
non adenomas. These included a metastasis from lung cancer and an 
incidentally detected metastasis. The values were 99.2% and 65.1% 
respectively. 
It also failed to characterise 1 adenoma. This was in a patient with a 
lung primary, which it ruled as non adenoma. The value was 57.4% 
Relative percent washout correctly characterised 23 of 25 adenomas 
and 26 of 29 non adenomas. The sensitivity and specificity were 92% and 
89.7% respectively. The positive and negative predictive values were 
88.5% and 92.7% respectively. 
Relative percentage washout failed to correctly characterise three 
non adenomas. These included a metastasis from lung cancer and two 
incidentally detected metastases. The values were 41.5%, 47% and 42.4% 
respectively. 
It also failed to characterise 2 adenomas. These included patients 
with an incidentally detected adenoma and a case of Cushing’s syndrome 
which was also pathologically proven to be an adenoma. Both of them 
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were characterised as non adenomas. The value was 34.9% and 37.7% 
respectively. 
The ability of unenhanced CT densitometry to help diagnose adrenal 
adenomas has been extensively studied. A number of these investigations 
established that adenomas consistently have lower attenuation values than 
nonadenomas. 
The amount of intratumoral lipid content of resected adrenal 
adenomas has directly correlated with a lower attenuation value at 
unenhanced CT. 
Thus threshold of 10 HU on unenhanced CT images was used as a 
cutoff for the inclusion criteria.  
Based on previous studies conducted on adrenal masses and their 
unenhanced attenuation values, it has been established that masses with 
very low unenhanced attenuation values are adenomas with high sensitivity 
and specificity. Thus a mass that is 10 HU or less on unenhanced CT 
images is diagnosed radiologically as an adenoma and a CT contrast 
washout study is not undertaken. 
Based on the attenuation values at unenhanced, enhanced and 
delayed enhanced CT and calculations of absolute and relative percentage 
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enhancement washouts, adenomas demonstrate a greater percentage of 
enhancement washout compared with nonadenomas.  
The results of this study confirms those of prior studies and 
demonstrates that the mean attenuation values at unenhanced CT adrenal 
adenomas and those of nonadenomas are nearly identical. 
Although the two groups have significantly different mean 
attenuation values at both enhanced and delayed enhanced CT, the 
considerable overlap between the two groups is too large to permit 
sufficiently accurate differentiation between them for any individual case. 
The distribution of the enhancement washout calculations for the 
two groups, however, was significantly different to allow accurate 
differentiation of individual cases.  
Absolute percent washout correctly characterised 51 of 54 adrenal 
masses with an accuracy of 94.44% 
Relative percent washout correctly characterised 49 of 54 adrenal 
masses with an accuracy of 90.74% 
The relative enhancement washout value is an approximation of the 
true enhancement washout value; it relates the decrease in attenuation 
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value on delayed enhanced images to the initial enhanced value, instead of 
to the difference between the enhanced and the unenhanced values.  
Absolute enhancement washout values were more accurate than use 
of the relative enhancement washout value in the differentiation of 
adenomas from nonadenomas. 
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LIMITATIONS OF THE STUDY 
Only 50 patients and 54 adrenal masses were included in the study. 
This patient population may be small. This results are to be considered 
preliminary and in need of further evaluation. Future studies involving 
large patient groups may be helpful to determine the usefulness of this 
technique for specific adrenal lesions. 
The study did not include masses with unenhanced attenuation 
values less than 10HU. Although previous studies have established that 
masses below 10HU are adenomas, there may be a few cases that could be 
exceptions. 
Third, partial volume averaging errors could have been made in the 
measurements of smaller masses. This may have falsely lowered or raised 
the recorded attenuation values. 
 
 
Conclusion 
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CONCLUSION 
Adenomas can be differentiated from nonadenomas at delayed 
enhanced CT examinations with absolute and relative percentage 
enhancement washout calculations.  
This protocol enables nearly all adrenal masses to be diagnosed with 
a high sensitivity and specificity. 
Thus CT contrast washout study for adrenal masses plays a 
definitive role in guiding clinical management.  
CASE 1 
     
 
 
 
Absolute Percent 
Washout 
34.9 Non adenoma Correct 
Relative Percent 
Washout 
29.1 Non adenoma Correct 
Pathological 
Diagnosis 
Metastasis Non adenoma  
Fig 20a : Plain - HU 13.1 Fig 20b:Enhanced - HU 78.8 
Fig 20c :Delayed – HU 55.9 
CASE 2 
        
 
 
   
Absolute Percent 
Washout 
23.8 Non adenoma Correct 
Relative Percent 
Washout 
17.0 Non adenoma Correct 
Pathological 
Diagnosis 
Metastasis Non adenoma  
Fig 21a: Plain - HU 26.9 Fig 21b:Enhanced - HU 94.1 
Fig 21c : Delayed – HU 78.1 
 CASE 3 
       
 
 
Absolute Percent 
Washout 
73.0 Adenoma Correct 
Relative Percent 
Washout 
55.6 Adenoma Correct 
Pathological 
Diagnosis 
Adenoma Adenoma  
Fig 22a : Plain - HU 12 Fig 22b: Enhanced - HU 22.3 
Fig 22c : Delayed – HU 50.2 
 CASE 4 
     
 
 
 
Absolute Percent 
Washout 
6.5 Non adenoma Correct 
Relative Percent 
Washout 
3.1 Non adenoma Correct 
Pathological 
Diagnosis 
Adrenocortical 
carcinoma 
Non adenoma  
Fig 23a  : Plain - HU 31.1 Fig 23b : Enhanced - HU 58.6 
Fig 23c : Delayed – HU 56.8 
 CASE 5 
     
 
 
 
Absolute Percent 
Washout 
71.0 Adenoma Incorrect 
Relative Percent 
Washout 
20.6 Non adenoma Correct 
Pathological 
Diagnosis 
Pheochromocytoma Non adenoma  
Fig 24a: Plain - HU 44.9 Fig 24b : Enhanced - HU 63.2 
Fig 24c : Delayed – HU 50.2 
CASE 6 
     
 
 
 
 
 
 
Absolute Percent 
Washout 
99.2 Adenoma Incorrect 
Relative Percent 
Washout 
42.4 Adenoma Incorrect 
Pathological 
Diagnosis 
Metastasis Non adenoma  
Fig 25a : Plain - HU 33.6 Fig 25b: Enhanced - HU 58.7 
Fig 25c: Delayed – HU 33.8 
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Annexures 
 
 
 
PROFORMA 
 
 “CHARACTERIZATION OF ADRENAL MASSES WITH 
CONTRAST ENHANCED CT”  
 
Sl.No:                                                                Date: 
Name:                                                               IP No: 
Age/Sex: 
         Occupation:                                                       
Address: 
 
Presenting Complaints 
                                                                         Yes           No 
Abdominal Pain               : 
Abdominal mass              : 
Loss of Appetite              : 
Loss of weight                 : 
Cough   :  
Hemoptysis   : 
Hametemesis                   : 
Haematuria   : 
Others                              : 
Past History 
H/O similar episodes before    - 
H/O Abdominal surgery            -  
Others                                         - 
 
Vital signs 
 
Pulse                                       - 
BP                                           - 
Respiratory rate                    - 
 
Examination of Abdomen 
 
Abdomen tenderness                 - 
Abdomen mass                          - 
Others    -  
 
Lab finding                                    
 
Complete blood profile  - 
Blood glucose   - 
Blood urea    - 
Creatinine    - 
Other     - 
Chest X ray findings: 
 
Baseline USG findings           
 
CT Chest findings (if taken) 
 
MRI Abdomen & PET scan (if taken) 
 
CECT Abdomen findings         
  
Side of adrenal mass     : 
 
Size         : 
 
Attenuation value in Plain CT    : 
 
Attenuation value in Contrast CT 1 minute study : 
 
Attenuation value in Contrast CT 15 minute study : 
 
Absolute washout ratio     : 
 
Relative washout ratio     : 
 
Adenoma/ /Non adenoma    : 
  
 
HPE findings            
 ABBREVIATIONS 
 
P   –   Unenhanced HU Value 
E   –   Enhanced HU Value 
D   –   Delayed HU Value 
APW  –   Absolute Percentage Washout 
RPW  –   Relative Percentage Washout 
R APW  –   Result based on Absolute Percentage 
Washout 
R RPW  –   Result based on Relative Percentage 
Washout 
Path   –   Histopathological Result 
 
MASTER CHART 
S no Patient Age Sex History Side Size P E D APW RPW R APW R RPW Path 
1 Sathya 29 F Incidental R 3.1 13.1 78.8 55.9 34.8 29.1 NA NA NA 
2 Meena 60 F Lung mass R 3.2 26.9 94.1 78.1 23.8 17 NA NA NA 
3 Thuravudeen 50 M Hypertension L 3.3 18.3 77.1 45.1 54.4 41.5 NA A NA 
4 Chandrasekar 48 M Lung mass R 4.1 33.6 58.7 33.8 99.2 42.4 A A NA 
5 Perumal 65 M Lung mass R 6.3 34.9 64.8 48.1 55.8 25.8 NA NA NA 
6 Perumal 65 M Lung mass L 4.5 38.6 59.9 52.1 36.6 13.6 NA NA NA 
7 Kesavan 63 M Abd pain L 3.4 12.1 60.1 30.5 61.7 49.3 A A A 
8 Chinnakannu 45 M Incidental R 3.7 22.4 53 36.5 53.9 31.1 NA NA NA 
9 Pattu 70 F Renal mass R 5.9 31.1 58.6 44.5 51.3 24.1 NA NA NA 
10 Mariammal 40 F Incidental R 3.7 26.3 68.4 35.9 77.2 47.5 A A A 
11 Jagadeesan 69 M Abd pain L 4.7 32 78.7 52.2 56.7 33.7 NA NA NA 
12 Jeeva 36 M Hypertension L 3.8 25.8 50.4 32.8 71.5 34.9 A NA A 
13 Raniammal 58 F Colon cancer R 4 24.1 76.1 43 63.6 43.5 A A A 
14 Sivaraman 35 M Abd pain R 2.8 31.6 78.5 41.2 79.5 47.5 A A A 
15 Govindammal 72 F Bone mets L 3.1 35.1 78.7 53.1 58.7 32.5 NA NA NA 
16 Pasupathy 67 M Lung mass R 2.5 18.9 65.7 35.3 65 46.3 A A A 
17 Pushpa 42 F Incidental L 3.1 24.4 67.5 43.1 56.6 36.1 NA NA NA 
18 Palani 59 M Liver metastasis R 3.2 19.9 53.6 31.1 66.8 42 A A A 
19 Peter 57 M Liver metastasis L 5.1 28.4 56.3 41.5 53 26.3 NA NA NA 
20 Helen 68 F Lung mass R 3.3 26.1 89 43.3 72.7 51.3 A A A 
S no Patient Age Sex History Side Size P E D APW RPW R APW R RPW Path 
21 Xavier 55 M Incidental L 3.4 25.8 51.6 34.8 65.1 32.5 A NA NA 
22 Xavier 55 M Incidental R 3.4 28.4 89.1 50.2 64.6 43.6 A A A 
23 Fathima 62 F Lung secondaries R 3.1 22.9 56.4 38.6 53.1 31.6 NA NA NA 
24 Chandrasekar 48 M Lung mass L 4.3 36.1 67.2 49.9 55.6 25.7 NA NA NA 
25 Annammal 56 F Lung mass R 3.6 21.5 61.6 38.1 58.6 38.1 NA NA NA 
26 Vadivel 46 M Incidental L 4.6 15.1 75.3 39.9 58.8 47 NA A NA 
27 Munirathnam 29 M Cushing's R 3.5 24 63.1 39.3 60.9 37.7 A NA A 
28 Banumathy 28 F Hypertension R 5.1 36.3 77.1 53.2 58.6 31 NA NA NA 
29 Nambirajan 57 M Lung mass L 3.7 18.3 78.9 44.1 57.4 44.1 NA A A 
30 Suseela 61 F Lung mass L 3.5 24.6 76.1 42.1 66 44.7 A A A 
31 Dawood 67 M Incidental R 6.1 29.4 77.3 52.1 52.6 32.6 NA NA NA 
32 Arockiamary 69 F Renal mass R 3.2 27.8 59.9 41.6 57 30.5 NA NA NA 
33 Dhanasekar 61 M Lung mass R 2.7 23.4 78.3 45.2 60.3 42.3 A A A 
34 Kasiamma 46 F Lung secondaries L 2.8 26.6 88.5 50.6 61.2 42.8 A A A 
35 Zahirabanu 36 F Pelvic pain L 3 31.4 98.5 57.4 61.2 41.7 A A A 
36 Francis 71 M Incidental R 4.4 33.3 68.3 48.1 57.7 29.6 NA NA NA 
37 Ezhilarasu 49 M Incidental L 3.7 24.4 59.6 48 55.9 19.9 NA NA NA 
38 Ponnamma 75 F Lung mass R 2.7 23.4 68.1 46.4 48.5 31.9 NA NA NA 
39 Muthuvelu 71 M Lung mass L 3.3 26.7 69.5 39.4 70.3 43.3 A A A 
40 Ramasamy 57 M Lung secondaries R 2.9 23.8 75.3 48.5 52 35.6 NA NA NA 
41 Seetha 34 F Incidental R 4.1 19.9 66 37.9 60.9 42.5 A A A 
S no Patient Age Sex History Side Size P E D APW RPW R APW R RPW Path 
42 Valarmathi 50 F Lung mass L 4.1 24.5 81.3 43.9 65.8 46 A A A 
43 Veerasamy 45 M Incidental L 4.9 32.2 64.3 46.4 55.8 27.8 NA NA NA 
44 Dhayalan 24 M Incidental R 3.4 18.3 69.9 37.8 62.2 45.9 A A A 
45 Lakshmi 58 F Lung mass R 5.1 17.1 73.1 38.2 62.3 47.7 A A A 
46 Ponnuthai 73 F Bone mets L 3.8 32.4 95.4 56.1 62.4 41.2 A A A 
47 Radhammal 26 F Hypertension L 5.7 21.1 45.4 32.1 54.7 29.2 NA NA NA 
48 Manickam 61 M Incidental R 5.2 26.3 67.2 45.2 53.8 32.7 NA NA NA 
49 Muthu 23 M Incidental L 4.7 25.1 97.1 51 64 47.5 A A A 
50 Samundi 32 M Abd pain R 2.5 18.5 59.1 31.1 68.9 47.4 A A A 
51 Samundi 32 M Abd pain L 3.2 21.6 82.1 43.8 63.3 46.7 A A A 
52 Feroz 57  Abd pain R 3.7 27.5 60.3 42.2 55.2 30 NA NA NA 
53 Srija 29 F Incidental R 3.1 22.4 73.6 38.3 68.9 48 A A A 
54 Susaiammal 61 F Incidental L 3.9 24.5 59 41.4 51 29.8 NA NA NA 
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 Title: CHARACTERIZATION OF ADRENAL MASSES WITH CONTRAST ENHANCED 
CT – WASHOUT STUDY 
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Coauthors : Prof.Dr.K.Vanitha, Prof.N.Kailasanathan, Prof.R.Malathy, Prof.S.Kalpana, 
Prof.S.Babu Peter, Prof.D.Ramesh, Dr.S.Sundareswaran, Dr.J.Devimeenal, Dr.Manimekala, 
Dr.J.Chezhian, Dr.K.Geetha 
Institution: Barnard Institute of Radiology, Madras Medical College. 
Aim of the study: To prospectively characterize adrenal masses as adenomas or non 
adenomas with Contrast enhanced CT and correlate with histopathological results 
Materials & Methods:  Fifty four adrenal masses were evaluated. CT attenuation values 
were measured using a circular region of interest on images of the lesion, covering at least 
one half of the mass. Adrenal masses that had attenuation values greater than 10 HU at 
unenhanced imaging underwent enhanced CT imaging 60 seconds after intravenous 
administration of contrast material and then underwent delayed enhanced CT imaging at 15 
minutes. Enhancement washout percentages were calculated with the following equations:  
Absolute percentage of enhancement washout:  
([Attenuation value at enhanced CT - Attenuation value at delayed enhanced CT]/ 
[Attenuation value at enhanced CT - Attenuation value at unenhanced CT]) * 100.  
Relative percentage of enhancement washout: 
([Attenuation value at enhanced CT - Attenuation value at delayed enhanced CT]/ 
Attenuation value at enhanced CT) * 100.  
An adenoma was diagnosed if a mass had an absolute percentage enhancement washout value 
of 60% or higher or relative percentage enhancement washout value of 40% or higher.  
Results: The pathological diagnosis was 25 adenomas and 29 non adenomas. Absolute 
percent washout diagnosed 24 of 25 adenomas and 27 of 29 non adenomas. It had a 
Sensitivity of 96.00%, Specificity of 93.10%, Positive Predictive Value of 92.31% and 
Negative Predictive Value of 96.43%. Relative percent washout diagnosed 23 of 25 
adenomas and 26 of 29 non adenomas. It had a sensitivity of 92%, specificity of 89.66%, 
Positive Predictive value of 88.46% and Negative Predictive Value of 92.86%. Both were 
found to be statistically significant. 
 
Conclusion. CT contrast washout study is helpful in categorising adenomas and non 
adenomas in adrenal masses with high degree of accuracy, sensitivity and specificity and 
helps guide clinical management. 
